Tumor Necrosis Factor Ligand Superfamily Member 14
"Tumor Necrosis Factor Ligand Superfamily Member 14" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of tumor necrosis factor superfamily found on activated LYMPHOCYTES and MONOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to LYMPHOTOXIN BETA RECEPTOR and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14.
|Tumor Necrosis Factor Ligand Superfamily Member 14
- Tumor Necrosis Factor Ligand Superfamily Member 14
- TNFSF14 Protein
- LIGHT Protein
- TNF Superfamily, Member 14
- Herpesvirus Entry Mediator-Ligand Protein
- Herpesvirus Entry Mediator Ligand Protein
- HVEM-L Protein
- HVEM L Protein
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Ligand Superfamily Member 14".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Ligand Superfamily Member 14".
This graph shows the total number of publications written about "Tumor Necrosis Factor Ligand Superfamily Member 14" by people in this website by year, and whether "Tumor Necrosis Factor Ligand Superfamily Member 14" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor Ligand Superfamily Member 14" by people in Profiles.
Unique Sj?gren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford). 2020 04 01; 59(4):860-868.
Immunotherapy and tumor microenvironment. Cancer Lett. 2016 Jan 01; 370(1):85-90.
LIGHT/TNFSR14 can regulate hepatic lipase expression by hepatocytes independent of T cells and Kupffer cells. PLoS One. 2013; 8(1):e54719.
LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res. 2012 Jun 15; 72(12):2980-9.
From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis. 2010 Jan; 69(1):297-300.
Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. J Immunol. 2010 Feb 01; 184(3):1589-95.
Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev. 2009 May; 229(1):232-43.
Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 2008 Jun-Aug; 19(3-4):285-94.
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science. 2007 Apr 13; 316(5822):285-8.